Patent application number | Description | Published |
20100137945 | AUTOMATED VERIFICATION OF MRI COMPATIBILITY OF ACTIVE IMPLANTABLE MEDICAL DEVICE - A system may include a processor configured to automatically obtain magnetic resonance imaging compatibility information relating to compatibility of an active implantable medical device implantable in a patient with an MRI modality from at least two information sources. The processor may also be configured to automatically determine compatibility of the active implantable medical device with the magnetic resonance imaging modality based on the magnetic resonance imaging compatibility information. | 06-03-2010 |
20100137946 | PATIENT-CENTRIC DATA COLLECTION FOR AUTOMATED MRI COMPATIBILITY VERIFICATION - A system may include a patient information terminal that receives magnetic resonance imaging compatibility information from a patient and a processor that automatically determines compatibility of an active implantable medical device with an magnetic resonance imaging modality based on the magnetic resonance imaging compatibility information. The magnetic resonance imaging compatibility information includes information relating to compatibility of the active implantable medical device implantable in the patient and the magnetic resonance imaging modality. | 06-03-2010 |
20100137947 | PATIENT PROGRAMMER WITH AUTOMATED MRI COMPATIBILITY VERIFICATION FOR ACTIVE IMPLANTABLE MEDICAL DEVICE - A system may include an active implantable medical device implantable in a body of a patient and a patient programmer for the AIMD. The patient programmer may be configured to obtain magnetic resonance imaging (MRI) compatibility information relating to compatibility of the AIMD with an MRI modality. | 06-03-2010 |
20120035616 | STEERING AN IMPLANTABLE MEDICAL LEAD VIA A ROTATIONAL COUPLING TO A STYLET - An implantable medical lead has a torsional stiffness and is rotationally coupled to a stylet. Applying rotation directly to the lead in turn causes rotation of the stylet. Where the stylet has a bent tip for purposes of steering the lead, the rotation applied to the lead rotates the bent tip so that the lead can be steered by rotating the lead rather than rotating a hub of the stylet. The rotational coupling may be achieved through one or more features provided for the lead and/or the stylet, such as a feature within a lumen of the lead that mates to a feature along the stylet or a feature of the stylet hub that engages the proximal end of the lead. The torsional stiffness of the lead may be provided by adding a feature within the lead body, such as a braided metal wire or an overlapping foil. | 02-09-2012 |
20120035695 | GROUNDING OF A SHIELD WITHIN AN IMPLANTABLE MEDICAL LEAD - Grounding of a shield that is located in an implantable medical lead may be done in many ways. The ground pathway may couple to the shield at a point that is outside of a header of an implantable medical device to which the implantable medical lead is attached. The ground pathway may couple to the shield at a point that is within the header of the implantable medical device. The ground pathway may terminate at the metal can of the implantable medical device. As another option, the ground pathway may terminate at a ground plate that is mounted to the header. The ground pathway may be direct current coupled from the shield to the can or ground plate. Alternatively, the ground pathway may include one or more capacitive couplings that provide a pathway for induced radio frequency current. | 02-09-2012 |
20120035696 | TERMINATION OF A SHIELD WITHIN AN IMPLANTABLE MEDICAL LEAD - A shield located within an implantable medical lead may be terminated in various ways. The shield may be terminated by butt, scarf, lap, or other joints between insulation layers surrounding the lead and an insulation extension. For lap joints, a portion of an outer insulation layer may be removed and a replacement outer insulation layer is positioned in place of the removed outer insulation layer, where the replacement layer extends beyond an inner insulation layer and the shield. The replacement layer may also lap onto a portion of the insulation extension. Barbs may be located between the replacement layer and the inner insulation layer or the insulation extension. The shield wires have ends at the termination point that may be folded over individually or may be capped with a ring located within one of the insulation layers of the jacket. | 02-09-2012 |
20120041528 | TERMINATION OF A SHIELD WITHIN AN IMPLANTABLE MEDICAL LEAD - A shield located within an implantable medical lead may be terminated in various ways at a metal connector. The shield may be terminated by various joints including butt, scarf, lap, or other joints between insulation layers surrounding the lead and an insulation extension. The shield may terminate with a physical and electrical connection to a single metal connector. The shield may terminate with a physical and electrical connection by passing between an overlapping pair of inner and outer metal connectors. The metal connectors may include features such as teeth or threads that penetrate the insulation layers of the lead. The shield may terminate with a physical and electrical connection by exiting a jacket of a lead adjacent to a metal connector and lapping onto the metal connector. | 02-16-2012 |
20120046722 | SHIELDING AN IMPLANTABLE MEDICAL LEAD - Implantable medical leads are shielded with a braided shield that surrounds an inner layer of insulation. An outer layer of insulation may also surround the shield. The shield is designed with parameters that limit the passage of radio frequency energy, particularly in the magnetic resonance imaging spectrum, to filars that are surrounded by the inner layer of insulation. The braided shield has a plurality of parameters and corresponding ranges. The parameters include one or more of braid angle, wire size, number of wires wound per direction, number of wires in a bundle, wire spacing in an axial dimension, ultimate tensile strength, cross-sectional wire shape, material, and distance from termination to a nearest electrode. Additional parameters of the lead related to the shielding also include one or more of inner insulation thickness, and outer insulation thickness. | 02-23-2012 |
20120130461 | RADIOPAQUE MARKERS FOR IMPLANTABLE MEDICAL LEADS, DEVICES, AND SYSTEMS - Radiopaque markers represent that a lead is suitable for a particular medical procedure such as a magnetic resonance image scan and are added to the lead or related device. The markers may be added after implantation of the lead in various ways including suturing, gluing, crimping, or clamping a radiopaque tag to the lead or to the device. The markers may be added by placing a radiopaque coil about the lead, and the radiopaque coil may radially contract against the lead to obtain a fixed position. The markers may be added by placing a polymer structure onto the lead where the polymer structure includes a radiopaque marker within it. The polymer structure may include a cylindrical aperture that contracts against the lead to fix the position of the structure. The polymer structure may form a lead anchor that includes suture wings that can be sutured to the lead. | 05-24-2012 |
20140222108 | PATIENT PROGRAMMER WITH AUTOMATED MRI COMPATIBILITY VERIFICATION FOR ACTIVE IMPLANTABLE MEDICAL DEVICE - A system may include an active implantable medical device implantable in a body of a patient and a patient programmer for the AIMD. The patient programmer may be configured to obtain magnetic resonance imaging (MRI) compatibility information relating to compatibility of the AIMD with an MRI modality. | 08-07-2014 |
20140345132 | TERMINATION OF A SHIELD WITHIN AN IMPLANTABLE MEDICAL LEAD - A shield located within an implantable medical lead may be terminated in various ways at a metal connector. The shield may be terminated by various joints including butt, scarf, lap, or other joints between insulation layers surrounding the lead and an insulation extension. The shield may terminate with a physical and electrical connection to a single metal connector. The shield may terminate with a physical and electrical connection by passing between an overlapping pair of inner and outer metal connectors. The metal connectors may include features such as teeth or threads that penetrate the insulation layers of the lead. The shield may terminate with a physical and electrical connection by exiting a jacket of a lead adjacent to a metal connector and lapping onto the metal connector. | 11-27-2014 |
20140350654 | GROUNDING OF A SHIELD WITHIN AN IMPLANTABLE MEDICAL LEAD - Implantable medical leads include a shield that is guarded at a termination by having a first portion and a second portion of the shield, where the first portion is between a termination of the shield at the second portion and an inner insulation layer that surrounds the filars. The first portion may reduce the coupling of RF energy from the termination of the shield at the second portion to the filars. The first and second portions may be part of a continuous shield, where the first and second portions are separated by an inversion of the shield. The first and second portions may instead be separate pieces. The first portion may be noninverted and reside between the termination at the second portion and the inner layers, or the first portion may be inverted to create first and second sub-portions. The shield termination at the second portion is between the first and second sub-portions. | 11-27-2014 |
Patent application number | Description | Published |
20090117625 | Polypeptides and Biosynthetic Pathways for the Production of Monatin and Its Precursors - Methods and compositions that can be used to make monatin from glucose, tryptophan, indole-3-lactic acid, indole-3-pyruvate, and 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid, are provided. Methods are also disclosed for producing the indole-3-pyruvate and 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid intermediates. Compositions provided include nucleic acid molecules, polypeptides, chemical structures, and cells. Methods include in vitro and in vivo processes, and the in vitro methods include chemical reactions. | 05-07-2009 |
20130203129 | POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS FOR THE PRODUCTION OF MONATIN AND ITS PRECURSORS - Methods and compositions that can be used to make monatin from glucose, tryptophan, indole-3-lactic acid, indole-3-pyruvate, and 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid, are provided. Methods are also disclosed for producing the indole-3-pyruvate and 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid intermediates. Compositions provided include nucleic acid molecules, polypeptides, chemical structures, and cells. Methods include in vitro and in vivo processes, and the in vitro methods include chemical reactions. | 08-08-2013 |
Patent application number | Description | Published |
20090287007 | PARTIALLY-HYDROGENATED, FULLY-EPOXIDIZED VEGETABLE OIL DERIVATIVE - Disclosed is a method for making a partially hydrogenated, fully epoxidized vegetable oil derivative. The method includes fully epoxidizing a partially hydrogenated vegetable oil having an iodine value of 70 to 100 g I | 11-19-2009 |
20100048754 | VISCOELASTIC POLYURETHANE FOAMS COMPRISING OLIGOMERIC NATURAL OIL POLYOLS - Described are viscoelastic polyurethane foams that comprise an oligomeric natural oil polyol and a petroleum-derived polyol. The viscoelastic foams are formed by reacting a polyisocyanate with an active-hydrogen composition that comprises the oligomeric natural oil polyol and petroleum-derived polyol. | 02-25-2010 |
20100087561 | VISCOELASTIC POLYURETHANE FOAMS COMPRISING AMIDATED OR TRANSESTERIFIED OLIGOMERIC NATURAL OIL POLYOLS - Described are viscoelastic polyurethane foams that comprise the reaction product of a polyisocyanate and an active-hydrogen composition comprising an amidated or transesterified oligomeric natural oil polyol. | 04-08-2010 |
20100240860 | NATURAL OIL-DERIVED POLYESTER POLYOLS AND POLYURETHANES MADE THEREFROM - A polyester polyol made from natural oil feedstocks is disclosed. Methods for making the polyol are also disclosed. The method comprises reacting monohydroxylated fatty acid/alkyl esters with a multifunctional ester-reactive initiator compound to form the polyester polyol. In one embodiment, the monohydroxylated fatty acid/alkyl esters are made by hydroxylating fatty acid/alkyl esters having greater than about ninety-five percent by weight monounsaturation. | 09-23-2010 |
20100267925 | NATURAL OIL-DERIVED POLYESTER POLYOLS AND POLYURETHANES MADE THEREFROM - A polyester polyol made from natural oil feedstocks is disclosed. Methods for making the polyol are also disclosed. The method comprises reacting hydroxylated fatty acid/alkyl esters with a multifunctional ester-reactive initiator compound to form the polyester polyol. In one embodiment, the hydroxylated fatty acid/alkyl esters are made by hydroxylating fatty acid/alkyl esters having up to ninety-five percent by weight monounsaturation. | 10-21-2010 |
20120136169 | POLYOLS MADE FROM PARTIALLY-EPOXIDIZED, FULLY-HYDROGENATED FATTY ACID ALKYL ESTERS - A method is described for producing polyester polyols by partially-epoxidizing fatty acid alkyl esters having an iodine value from 90 to 190 g I2/100 grams, fully-hydrogenating the partially-epoxidized esters to form hydroxylated fatty acid alkyl esters, and then reacting the hydroxylated fatty acid alkyl esters with a multifunctional ester-reactive initiator compound to form the polyester polyol. | 05-31-2012 |
20130150616 | METHODS OF MANUFACTURING DERIVATIVES OF BETA-HYDROXYCARBOXYLIC ACIDS - Preparation of derivatives of β-hydroxycarboxylic acid, including β-hydroxycarboxylic acid esters, α,β-unsaturated carboxylic acid, esters of α,β-unsaturated carboxylic acid, and alkoxy derivatives. | 06-13-2013 |
20130296451 | REACTION PRODUCT FROM THE CO-DEHYDRATION OF A SUGAR ALCOHOL AND A POLYOL - A reaction product of the co-dehydration of a sugar alcohol and a reactant polyol having a number average hydroxyl functionality less than 4.0 is disclosed. In some aspects the sugar alcohol comprises mannitol, sorbitol, xylitol, erythritol, or mixtures thereof. In some preferred aspects the sugar alcohol comprises sorbitol. In some aspects the reactant polyol has an average molecular weight of from 40 to 500 Daltons. In some aspects, the reaction product may be suitable for the manufacture of polyisocyanurate foam. In some aspects the reaction product may be mixed with diluent polyols, such as diols, glycols, ethylene glycol, diethylene glycol, dipropylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol and mixtures thereof. | 11-07-2013 |
20140364643 | METHODS OF MANUFACTURING DERIVATIVES OF BETA-HYDROXYCARBOXYLIC ACIDS - Preparation of derivatives of β-hydroxycarboxylic acid, including β-hydroxycarboxylic acid esters, α,β-unsaturated carboxylic acids, esters of α,β-unsaturated carboxylic acid, and alkoxy derivatives. | 12-11-2014 |